Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes

Jaime, J.; Klittich, Wendy S.; Raggio, Gabriel; Kavanagh, Patricia L.; O’Brien, Judith A.; Shomphe, Lori A.; Flegel, Ken; Copley-Merriman, Catherine; Sigler, Cathy

doi:10.1016/s0149-2918(00)87983-7

Cited by 22 publications

(37 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additional support for our analyses is provided by the finding that the costs of managing complications over 10 years were actually found to be reduced in patients with type 2 diabetes receiving intensive treatment rather than conventional therapy (55). Other shorterterm studies have also concluded that the costs of medical care are increased if HbA 1c levels exceed 7% (5) or 8% (56) and that a reduction from a baseline level of HbA 1c of 10% by at least 1% or more that was sustained over 2 years is associated with lower costs (6,18).…”

Section: Resultsmentioning

confidence: 99%

“…1) simulates patients with type 2 diabetes from diagnosis to death (18), including the occurrence of macrovascular complications (stroke, transient ischemic attack, myocardial infarction, and angina) and various levels of the progressive complications (nephropathy, retinopathy, and neuropathy), which start at the mildest level but can develop into major complications. For example, nephropathy has three levels: microalbuminuria, gross proteinuria, and end-stage renal disease (ESRD).…”

Section: Modelmentioning

confidence: 99%

“…In addition, previous analyses have been peer-reviewed (18). Technical accuracy was ascertained by implementing the model in two different ways and comparing the results, as well as by performing extreme-value sensitivity analyses to study its behavior.…”

Section: Modelmentioning

confidence: 99%

See 2 more Smart Citations

Lifetime Costs of Complications Resulting From Type 2 Diabetes in the U.S.

Jaime¹,

Ward²,

O’Brien³

2002

Diabetes Care

Self Cite

223

126

View full text Add to dashboard Cite

OBJECTIVE -To model the lifetime costs associated with complications of type 2 diabetes. RESEARCH DESIGN AND METHODS-A cohort of 10,000 patients with diabetes was simulated using a model based on existing epidemiological studies. Complication rates were estimated for various stages of macrovascular disease, nephropathy, retinopathy, neuropathy, and hypoglycemia. At the beginning of the simulation, patients were assumed to have been treated for 5 years and have a mean HbA 1c of 8.4. From the U.K. Prospective Diabetes Study, it was estimated that on current therapies, the HbA 1c would drift upward on average 0.15% per year. Direct medical costs of managing each complication were estimated (in 2000 U.S. dollars) from all-payor databases, surveys, and literature.RESULTS -Macrovascular disease was estimated to be the largest cost component, accounting for 85% of cumulative costs of complications over the first 5 years. The costs of complications were estimated to be $47,240 per patient over 30 years, on average. The management of macrovascular disease is estimated to be the largest cost component, accounting for 52% of the costs; nephropathy accounts for 21%, neuropathy accounts for 17%, and retinopathy accounts for 10% of the costs of complications.CONCLUSIONS -The complications of diabetes account for substantial costs, with management of macrovascular disease being the largest and earliest. If improving glycemic control prevents complications, it will reduce these costs. Diabetes Care 25:476 -481, 2002

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Modelmentioning

confidence: 99%

See 1 more Smart Citation

Lifetime Costs of Complications Resulting From Type 2 Diabetes in the U.S.

Jaime¹,

Ward²,

O’Brien³

2002

Diabetes Care

Self Cite

223

126

View full text Add to dashboard Cite

show abstract

“…The estimated costs and outcomes associated with diabetes were based on a previous diabetes model developed by the authors. 177,178 The diabetes submodel consisted of several Markov processes that were used to model disease progression on several complication pathways including retinopathy, nephropathy, neuropathy and CVD (stroke, transient ischaemic attacks, MI and angina). Individuals progressed through the model based on their starting characteristics (age, sex, HbA 1c ) and were tracked until death.…”

Section: Model Structure Perspective and Scopementioning

confidence: 99%

“…However, it is unclear from the paper how these characteristics were assigned to simulated patients and modelled to progress over time. From review of a previous version of the diabetes model used in this analysis, 177,178 it appears that patient characteristics were assigned by sampling from probability distributions. However, there is no mention in the current analysis of the distributions used for the IGT cohort.…”

Section: Modelling Disease Progressionmentioning

confidence: 99%

Screening for type 2 diabetes: literature review and economic modelling

Waugh¹,

Scotland²,

McNamee³

et al. 2007

Health Technol Assess

243

194

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as r...

show abstract

Current Awareness

2000

Diabetes Metab. Res. Rev.

View full text Add to dashboard Cite

In order to keep subscribers up-to-date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of diabetes/metabolism. Each bibliography is divided into 17 sections: 1 Books, Reviews & Symposia; 2 General; 3 Genetics; 4 Epidemiology; 5 Immunology; 6 Prediction; 7 Prevention; 8 Intervention: a&rpar General; b&rpar Pharmacology; 9 Pathology: a&rpar General; b&rpar Cardiovascular; c&rpar Neurological; d&rpar Renal; 10 Endocrinology & Metabolism; 11 Nutrition; 12 Animal Studies; 13 Techniques. Within each section, articles are listed in alphabetical order with respect to author (8 Weeks journals - Search completed at 19th Apr. 2000)

show abstract

Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes

Cited by 22 publications

References 26 publications

Lifetime Costs of Complications Resulting From Type 2 Diabetes in the U.S.

Lifetime Costs of Complications Resulting From Type 2 Diabetes in the U.S.

Screening for type 2 diabetes: literature review and economic modelling

Current Awareness

Contact Info

Product

Resources

About